Stocks and Investing
Stocks and Investing
Thu, July 29, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, July 28, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matt Miksic Maintained (BSX) at Buy with Increased Target to $52 on, Jul 28th, 2021
Matt Miksic of Credit Suisse, Maintained "Boston Scientific Corporation" (BSX) at Buy with Increased Target from $50 to $52 on, Jul 28th, 2021.
Matt has made no other calls on BSX in the last 4 months.
There are 2 other peers that have a rating on BSX. Out of the 2 peers that are also analyzing BSX, 1 agrees with Matt's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Mike Matson of "Needham" Downgraded from Strong Buy to Hold on, Wednesday, May 26th, 2021
This is the rating of the analyst that currently disagrees with Matt
- Travis Steed of "Barclays" Initiated at Buy and Held Target at $51 on, Tuesday, May 25th, 2021
Contributing Sources